Please enable Javascript
Yousef Zakharia, MD
Yousef Zakharia, MD, of University of Iowa Holden Comprehensive Cancer Center
Articles by Yousef Zakharia, MD
Refractory RCC: Third-Line Treatment Considerations
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
View More
Improving Outcomes in Patients With Chromophobe, Papillary RCC
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
View More
Personalized RCC Care: Decreasing Overtreatment, Identifying Cured Patients in the Adjuvant Setting
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
View More
Considerations for Managing Patients on Maintenance RCC Therapy
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
View More
CheckMate 67T: Do Recent Updates Make This Practice-Changing?
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
View More
RCC Treatment Sequencing and Combination Approaches: JAVELIN Renal 101 and COSMIC-313
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
View More
Guadecitabine and Durvalumab in Advanced Clear Cell RCC
Yousef Zakharia, MD
Advanced Renal Cell Carcinoma
|
April 25, 2024
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
View More
Epigenetic Regulation for Immune Evasion in Advanced Kidney Cancer
Yousef Zakharia, MD
Advanced Renal Cell Carcinoma
|
April 25, 2024
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
View More